Advanced searches left 3/3

Aliskiren - Crossref

Summarized by Plex Scholar
Last Updated: 16 August 2022

* If you want to update the article please login/register

Hypertension Management and End Organ Protection: Focus on Aliskiren

In fact, the optimized RAS suppression is difficult to achieve with these products, partially because ACE inhibitors and ARBs both stimulate compensatory feedback mechanisms that result in renin removal and increase plasma renin activity. This paper explores the mechanism of action of oral renin inhibitors and their pharmacokinetic properties. In addition, the paper reviews the available evidence on the use of the renin inhibitor aliskiren in the treatment of hypertension and related cardiovascular disorders.

Source link: https://doi.org/10.4137/cmt.s1980


Aliskiren Hemifumarate Proliposomes for Improved Oral Drug Delivery: Formulation Development, In Vitro and In Vivo Permeability Testing

aliskiren hemifumarate, a poorly bioavailable drug, was the aim of this research. Proproosomes were prepared using a solvent evaporation technique using different lipids. In 0. 01 N hydrochloric acid dissolution kit, a USP type II dissolution device, was used in vitro drug release experiments. To investigate in vitro drug permeation, parallel artificial membrane permeation assay and Caco-2 cell line models were used. In vitro pharmacokinetic studies were carried out with male Sprague-Dawley rats. Compared to pure AKH, the PAMPA and Caco-2 cell line experiments showed a significant increase in permeability of AKH with protons. The optimized formulation of proliposomes showed significant improvements in the rate and extent of AKH absorption in animal studies. Specifically, following single oral administration, the relative bioavailability of AKH proliposome formulation was 23 percent relative to pure AKH suspension.

Source link: https://doi.org/10.3390/molecules27154828


Aliskiren Regulates Neonatal Fc Receptor and IgG Metabolism with Attenuation of Anti-GBM Glomerulonephritis in Mice

Effects: IgG deposition and expressions of FcRn and PRR were boosted at glomeruli and urinary IgG levels in anti-GBM GN, with elevated FcRn and PRR. With decrease of proteinuria and cortical expressions of fibronectin and TGF-u03b21, Aliskiren attenuated anti-GBM GN. Even with higher circulating serum IgG levels, Aliskiren also reduced the glomerular IgG depositions and the urinary IgG levels. Conclusion: These results indicate that FcRn and PRR suppression as well as IgG metabolism control may have been attributed to anti-GBM GN's attenuation by aliskiren.

Source link: https://doi.org/10.1159/000448789


The Renin Inhibitor Aliskiren Attenuates High-Glucose Induced Extracellular Matrix Synthesis and Prevents Apoptosis in Cultured Podocytes

Aliskiren stops the renin-catalyzed conversion of angiotensinogen to angiotensin I. In vitro, this research investigated ALIu2019s effect on podocyte growth and survival in a high-glucose environment. Methods: For 24-24 h without and without ALI, conditionally immortalized mouse podocytes were incubated in normal glucose or high glucose for 24u201348 h. ALI significantly reduced the mRNA and protein levels of FN, Cola5IV, and TIMP1, as well as the mRNA of TIMP2 and cleaved caspase-3. MMP2 mRNA, protein, or MMP9 mRNA were not affected by ALI's HG conditions. TUNEL staining was discovered in podocytes cultured under HG conditions, which reduced the activated caspase-3 protein and signs of apoptosis. These results show that renin inhibition with ALI mitigates the profibrotic and apoptotic effects of HG in cultured podocytes for the first time. These results support the clinical justification for renin inhibition with ALI beyond its hemodynamic effects.

Source link: https://doi.org/10.1159/000322242


Effect of the Direct Renin Inhibitor Aliskiren in the Prevention of Experimental Contrast-Induced Nephropathy in the Rat

Methods: The thirty-two Wistar albino rats were divided into four groups of 8 rats each, including the control, aliskiren, comparison media, and aliskiren plus contrast media groups. Aliskiren was given orally at a dose of 50 mg/kg/day for five days in a row. In the ACM group, mean serum creatinine was significantly lower, and mean creatinine clearance was higher than in the CM group relative to the CM group. Conclusion: Our preliminary results point to a possible role of aliskiren in CIN's prophylaxis.

Source link: https://doi.org/10.1159/000336104


Antidepressant-like Effects of Renin Inhibitor Aliskiren in an Inflammatory Mouse Model of Depression

Depression is a global epidemic that is also connected with disability and can be related to disability. The pathophysiology of depression is not well understood, but recent research has shown that neuroinflammation may be responsible for depression symptoms. The LPS administration in OFT reduced the number of crossings in OFT, reducing the number of crossings in OFT, according to the Aliskiren pretreatment, which delayed the LPS effect for two hours after LPS injection. In OFT 24 hours after LPS administration, the drugs did not have an effect on locomotor activity. After 24 hours, Aliskiren halted the effects induced by LPS in TST, FST, and SPT. However, Aliskiren reduced LPS-induced inflammation genes in the prefrontal cortex, according to a study by Aliskiren. Hence, the findings reveal that Aliskiren does not cause depressive disorders in humans linked to neuroinflammation.

Source link: https://doi.org/10.3390/brainsci12050655


Effects 0f Aliskiren on the Absorption of Monosaccharides in Animal Model of Fructose-induced Metabolic Syndrome

In addition, blood absorption of glucose was markedly reduced after oral glucose load in high-fructose diet fed rats. After oral glucose intake in high fructose-fed rats, aliskiren dramatically reduces body weight, fasting serum glucose, insulin, triglyceride, and total cholesterol levels, as well as the rate of glucose absorption.

Source link: https://doi.org/10.32947/ajps.v17i2.45


Abstract 184: Deterioration of Kidney Function by the (Pro)renin Receptor Blocker Handle Region Peptide in Aliskiren-treated Diabetic Transgenic (mRen2)27 Rats

The level of prorenin in diabetic patients with diabetes mellitus may be affected by the degree of prorenin bindement to the renin receptor and subsequent angiotensin production and/or the direct agonistic effects of prorenin mediated by this receptor. Moreover, elevated prorenin levels in DM are correlated with the onset of microvascular diseases such as nephropathy. Methods and Design In this research, renal function in diabetic TGR27 rats injected with vehicle, the renin inhibitor aliskiren, or aliskiren plus the putative RR antagonist HRP for three weeks was evaluated. Aliskiren's increased rat renin expression in the renal cortex. In the aliskiren+HRP group, the aliskiren+HRP group's glossular volume and interlobar arterial lumen diameter marginally increased, while aliskiren unaffected by aliskiren alone. When given on top of aliskiren in DM TGR27 rats, the kidney damage increases kidney disease and counteracts the beneficial effects of aliskiren, according to Conclusions HRP.

Source link: https://doi.org/10.1161/hyp.62.suppl_1.a184


Abstract 024: The Direct Renin Inhibitor Aliskiren Improves Vasodilation and Endothelial Function in Resistance Arteries from Diabetic and Hypertensive Patients

We previously reported that the direct renin inhibitor aliskiren significantly reduced the subcutaneous resistance arteries of hypertensive patients in comparison to the angiotensin-converting enzyme inhibitor ramipril. We wondered if endothelial function of resistance arteries would improve after 1 year of blood pressure monitoring with ALK or RAM. Patients with mild essential hypertension were randomized to ALK or RAM. Both ALK and RAM were significantly and equally reduced, while diastolic BP was only reduced in ALK-treated but not in RAM-treated patients. PWV and FMD were identical in both groups before and after treatment, and after care. In both groups before and after therapy, the markers of oxidative stress remained the same in both groups. In conclusion, ALK improved endothelial function and caused vasodilation in resistance arteries from diabetic and hypertensive patients.

Source link: https://doi.org/10.1161/hyp.66.suppl_1.024


Angiotensin II Suppression in Humans by the Orally Active Renin Inhibitor Aliskiren (SPP100)

Using a double-blind, 3-way crossover protocol, we tested the latest orally active nonpeptidic renin inhibitor SPP100 in 18 healthy volunteers on a steady 100 mmol/d sodium diet using a double-blind, 3-way crossover protocol. Following single doses of Aliskiren starting with 40 mg, the highest dose of Ang II was still present and significant, with maximum decreases in plasma renin activity, Ang I and Ang II, respectively. Inhibition declines in Ang II and Ang II ranging from 80 percent to 75 percent on Days 1 and 8, respectively, when the highest dose of Aliskiren was compared to placebo was seen. After taking Aliskiren u226580 mg and enalapril, plasma and urinary aldosterone levels were reduced following the intake of enalapril. Aliskiren has the potential to become the first orally active renin inhibitor in therapy for hypertension and other cardiovascular and renal disorders.

Source link: https://doi.org/10.1161/hy0102.102293

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions